Designed to kill: novel menin-MLL inhibitors target MLL-rearranged leukemia
- PMID: 25873167
- DOI: 10.1016/j.ccell.2015.03.012
Designed to kill: novel menin-MLL inhibitors target MLL-rearranged leukemia
Abstract
The interaction between menin and oncogenic mixed lineage leukemia (MLL) fusion proteins is required for leukemic transformation and may represent a therapeutic opportunity. In this issue of Cancer Cell, Borkin and colleagues describe the development of highly potent small-molecule inhibitors of this interaction that reverse the leukemic phenotype and prolong survival in murine models of MLL-rearranged leukemia.
Copyright © 2015 Elsevier Inc. All rights reserved.
Comment on
-
Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.Cancer Cell. 2015 Apr 13;27(4):589-602. doi: 10.1016/j.ccell.2015.02.016. Epub 2015 Mar 26. Cancer Cell. 2015. PMID: 25817203 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
